Similar to JAKs, TYK2 is an important mediator of innate and adaptive immune activation. Unlike JAKs, however, TYK2 is thought to play a minimal role in other pathways, such as metabolic and hematopoietic axes. Therefore, it is hypothesized that TYK2-targeted agents could be effective in rheumatic disease, with a potential for less off-target adverse effects. Zasocitinib is a new, oral TYK2 inhibitor generated using artificial intelligence-

Despite the remarkable expansion of the therapeutic armamentarium for psoriatic arthritis (PsA), the MONITOR-PsA study highlights a persistent and critical issue: delays in diagnosis. The study findings are stark, with about 25% of patients having erosions at diagnosis.

A recent study presented at #ACR24 convergence highlights significant gaps and inconsistencies in the research of systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still’s disease (AOSD). Analyzing 195 studies with over 18,000 patients, they found considerable variation in clinical and outcome measures between pediatric and adult cohorts.